Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders
Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders
Herantis Pharma Plc
Company release 11 April 2017 at 4:00 PM
The Annual General Meeting of Shareholders of Herantis Pharma Plc was held in Helsinki on Tuesday, 11 April 2017.
Matters pertaining to the Annual General Meeting
The Annual General Meeting adopted the consolidated financial statements and the parent company's financial statements for the financial year 2016 and discharged the members of the Board of Directors and the CEO from liability. The Annual General Meeting of Shareholders decided that, as proposed by the Board of Directors, no dividend be paid for the financial year 1 January - 31 December 2016 and that the loss for the financial year shall be entered in the account for profit and loss.
The Annual General Meeting resolved that the remuneration payable to the members of the Board of Directors shall be EUR 1,000 per month except for the Chairman of the Board who shall be paid EUR 2,000 monthly. It was further resolved that the board members shall also be eligible to subscribe to stock options of option program 2014 I, according to the rules of which the board members can be given stock options for each full 12 month period as a Board member. Board members are also reimbursed reasonable travel expenses related to Board of Director's duties.
The Annual General Meeting decided that the Auditor will be paid reasonable remuneration in accordance with the invoice approved by the Company.
The firm of authorised public accountants PricewaterhouseCoopers Oy was appointed as Herantis Pharma Plc's Auditor for the term ending at the end of the next Annual General Meeting of Shareholders, with APA Martin Grandell as the responsible auditor.
HERANTIS PHARMA PLC
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine for breakthrough in unmet clinical needs. Our first-in-class assets are based on globally leading scientific research in their fields: CDNF for disease modification in neurodegenerative diseases, primarily Parkinson's and ALS; and Lymfactin® for breast cancer associated lymphedema, with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.